**Core Concept:**
Ulnar neuritis is a condition caused by damage or inflammation of the ulnar nerve, which can result in weakness or paralysis of the muscles innervated by this nerve. In borderline tuberculoid leprosy, the immune response is generally mild, and the disease progression is slower. Treatment depends on the severity of the neuritis and its impact on the patient's functional status.

**Why the Correct Answer is Right:**
In the context of borderline tuberculoid leprosy, the correct answer involves considering the disease severity and the patient's functional status. In this case, the correct answer is D) Rifampicin, Clofazimine, and Methylene Blue therapy, which is a standard treatment for borderline leprosy. This combination helps to control the disease progression and prevent further nerve damage, thus reducing the likelihood of severe ulnar neuritis.

**Why Each Wrong Option is Incorrect:**
A) Dapsone alone is not effective in treating severe ulnar neuritis, as it primarily targets M. leprae and has limited impact on the immune response and nerve damage.

B) Multidrug therapy (MDT) is a recommended treatment for paucibacillary leprosy cases (lepromatous, borderline lepromatous, or LL) but is not specifically designed for borderline tuberculoid leprosy and ulnar neuritis.

C) Methotrexate is a drug used in rheumatological conditions, not for treating leprosy or nerve injuries.

**Clinical Pearl:**
The correct answer (D) demonstrates the importance of tailoring treatment options based on disease severity and patient-specific factors in dermatological conditions, particularly in borderline cases. In borderline tuberculoid leprosy, a combination of Rifampicin, Clofazimine, and Methylene Blue therapy is used to manage the disease progression and prevent severe ulnar neuritis. This highlights the need for individualized treatment plans in dermatological conditions to optimize patient outcomes.